A study of fasting and the ketogenic diet reveals a new vulnerability of pancreatic tumors to an existing cancer drug.
FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted to a smaller group
Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts